PODXL2 (podocalyxin-like 2) is a transmembrane sialomucin belonging to the CD34 family that functions as a cellular adhesion protein with significant roles in cancer progression and development. The protein is proteolytically processed by ADAM10 and regulates neurite branching in primary neurons, with endoglycan deficiency reducing neurite branching while ADAM10 deletion increases it 1. In cancer contexts, PODXL2 demonstrates oncogenic properties, maintaining cellular stemness and promoting tumor development through the Rac1/Akt pathway in breast cancer, where overexpression correlates with poor patient survival 2. In prostate cancer, elevated PODXL2 expression is associated with poorer progression-free survival and advanced disease characteristics, while its silencing reduces cell proliferation, invasion, epithelial-mesenchymal transition, and immune escape through PI3K/AKT pathway inactivation 3. PODXL2 also serves as a target of miR-127 in hair follicle stem cell differentiation, where its downregulation inhibits stem cell differentiation into basal layer cells during wound healing processes 4. The gene has been identified as a biomarker in various cancer types, including lung adenocarcinoma for lymph node metastasis prediction 5 and as part of prognostic signatures in sarcoma 6.